Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Santos EstebanOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-6,137Price:$268.87
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Reese David MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-6,202Price:$268.87
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Miller DerekOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-475Price:$268.87
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Khosla RachnaOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-438Price:$268.87
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Grygiel Nancy A.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-703Price:$268.87
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Griffith Peter H.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-5,168Price:$268.87
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Graham Jonathan POwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-5,879Price:$268.87
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Gordon MurdoOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-6,461Price:$268.87
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Busch Matthew C.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-146Price:$268.87
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Bradway Robert AOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-20,560Price:$268.87
Filings by filing date
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Santos EstebanOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-6,137Price:$268.87
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Reese David MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-6,202Price:$268.87
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Miller DerekOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-475Price:$268.87
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Khosla RachnaOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-438Price:$268.87
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Grygiel Nancy A.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-703Price:$268.87
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Griffith Peter H.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-5,168Price:$268.87
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Graham Jonathan POwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-5,879Price:$268.87
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Gordon MurdoOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-6,461Price:$268.87
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Busch Matthew C.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-146Price:$268.87
-
Mar 18, 2024 (filed on Mar 20, 2024)Insider Name:Bradway Robert AOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-20,560Price:$268.87
News
Biz Brief
Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | One Amgen Center Drive THOUSAND OAKS CA 91320 |
Tel: | N/A |
Website: | https://www.amgen.com |
IR: | See website |
Key People | ||
Robert A. Bradway Chairman of the Board, President, Chief Executive Officer | Rachna Khosla Senior Vice President - Business Development | Peter H. Griffith Chief Financial Officer, Executive Vice President |
David M. Reese Executive Vice President, Chief Technology Officer | James Bradner Executive Vice President, Research and Development, and Chief Scientific Officer | Jonathan P. Graham Executive Vice President, General Counsel, Secretary |
Lori A. Johnston Executive Vice President - Human Resources | Murdo Gordon Executive Vice President - Global Commercial Operations | Esteban Santos Executive Vice President - Operations | Nancy A. Grygiel Senior Vice President, Chief Compliance Officer |
Business Overview |
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company's marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others. |
Financial Overview |
For the fiscal year ended 31 December 2023, Amgen Inc revenues increased 7% to $28.19B. Net income increased 3% to $6.72B. Revenues reflect TEPEZZA segment increase from $0K to $448M, Prolia segment increase of 12% to $4.05B, US segment increase of 9% to $19.27B, ROW segment increase of 8% to $7.64B. Net income was partially offset by Interest expense, net increase from $1.41B to $2.88B (expense), Selling. |
Employees: | 26,700 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $198,158M as of Dec 31, 2023 |
Annual revenue (TTM): | $28,190M as of Dec 31, 2023 |
EBITDA (TTM): | $12,235M as of Dec 31, 2023 |
Net annual income (TTM): | $6,717M as of Dec 31, 2023 |
Free cash flow (TTM): | $2,803M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $53,669M as of Dec 31, 2023 |
Shares outstanding: | 536,375,548 as of Apr 1, 2024 |
Index Membership: | S&P 500, Dow Industry |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |